The advisory panel wasn't convinced that a clinical trial proved that early switching to camizestrant improved long-term ...

The FDA’s Oncologic Drugs Advisory Committee (ODAC) on Thursday voted 6 to 3 that AstraZeneca has not demonstrated its oral ...

The British pharmaceutical group said it would continue to work with U.S. regulators on a review of its breast-cancer ...

While AstraZeneca has discontinued work on four assets—including one in asthma and another in acromegaly—the pharma has also ...

Sir Kier Starmer announces the multi-million-pound investment in the House of Commons.

The FDA’s real-time clinical trial mechanism allows drug sponsors to transmit data immediately to the regulator through the ...

AstraZeneca has paid $25 million to pick up a preclinical EGFR degrader that was at the center of its existing pact with ...

By Pushkala Aripaka and Maggie Fick April 29 (Reuters) - AstraZeneca beat first-quarter profit expectations and maintained ...

Baron Capital, an investment management company, released its Q1 2026 investor letter for the “Baron Health Care Fund”. A ...

Our AstraZeneca (NASDAQ:AZN | AZN Price Prediction) call comes one day after the British drugmaker reported Q1 2026 revenue ...

AstraZeneca reported robust first-quarter 2026 earnings, driven by strong demand for its oncology and rare disease treatments ...